HARMONY BIOSCIENCES HOLDINGS, INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $2.26 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2024-02-22
- HARMONY BIOSCIENCES HOLDINGS, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2019-12-31 was $2.00M.
- HARMONY BIOSCIENCES HOLDINGS, INC. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $2.26M.
- HARMONY BIOSCIENCES HOLDINGS, INC. research and development asset acquired other than through business combination, written-off for fiscal 2020 was $2.00M, a 96.15% decline from fiscal 2019.
- HARMONY BIOSCIENCES HOLDINGS, INC. research and development asset acquired other than through business combination, written-off for fiscal 2019 was $52.00M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|
| 2023-12-31 | $2.26M 10-K · filed 2024-02-22 | ||
| 2020-12-31 | $2.00M 10-K · filed 2023-02-21 | ||
| 2019-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $52.00M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $50.00M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |